Target Price | $5.31 |
Price | $1.05 |
Potential |
405.91%
register free of charge
|
Number of Estimates | 5 |
5 Analysts have issued a price target CytomX Therapeutics, Inc. 2025 .
The average CytomX Therapeutics, Inc. target price is $5.31.
This is
405.91%
register free of charge
$8.00
661.90%
register free of charge
$3.50
233.33%
register free of charge
|
|
A rating was issued by 7 analysts: 4 Analysts recommend CytomX Therapeutics, Inc. to buy, 3 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the CytomX Therapeutics, Inc. stock has an average upside potential 2025 of
405.91%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 101.21 | 100.21 |
90.39% | 0.99% | |
EBITDA Margin | -4.26% | -37.70% |
97.42% | 785.29% | |
Net Margin | -0.77% | -24.58% |
99.65% | 3,084.51% |
6 Analysts have issued a sales forecast CytomX Therapeutics, Inc. 2024 . The average CytomX Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast CytomX Therapeutics, Inc. 2024 . The average CytomX Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 CytomX Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average CytomX Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.01 | -0.32 |
99.34% | 3,100.00% | |
P/E | negative | |
EV/Sales | negative |
7 Analysts have issued a CytomX Therapeutics, Inc. forecast for earnings per share. The average CytomX Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the CytomX Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
CytomX Therapeutics, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.